In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Cingulate Inc (CING – Research Report), with a price target of $3.00. The company’s shares opened today at $1.05.
Rahman covers the Healthcare sector, focusing on stocks such as Clene, Quoin Pharmaceuticals, and scPharmaceuticals. According to TipRanks, Rahman has an average return of 4.8% and a 34.71% success rate on recommended stocks.
Cingulate Inc has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $2.00 and a one-year low of $0.66. Currently, Cingulate Inc has an average volume of 880.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
Read More on CING:
- Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
- Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
- Cingulate to Participate in Benzinga All Live Access Event
- Cingulate completes first cohort of Phase 3 trial of CTx-1301
- Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
